LifeMD (LFMD) AI Stock Analysis

• Market Cap: $240.41M
• Dividend Yield: N/A
• Average Volume (3M): 872.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 37.74%
• EPS Growth: 69.79%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.06
• Shares Outstanding: 47,417,393
• 10 Day Avg. Volume: 948,599
• 30 Day Avg. Volume: 872,568
• PEG Ratio: 0.44
• Price to Book (P/B): -37.17
• Price to Sales (P/S): 0.96
• P/FCF Ratio: 34.12
• Enterprise Value/Market Cap: 2.47
• Enterprise Value/Revenue: 2.55
• Enterprise Value/Gross Profit: 2.76
• Enterprise Value/Ebitda: 69.31
• 1Y Price Target: $14.50
• Price Target Upside: 213.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.13
• Revenue Forecast (FY): $253.07M

• Rating: 44 Neutral
• Price Target: $5.00 ▲(8.23% Upside)

LifeMD's overall stock score is primarily impacted by its financial performance, which is hindered by high leverage and negative profitability. Technical analysis indicates bearish momentum, further weighing down the score. Valuation metrics are unfavorable due to ongoing losses. While the earnings call provided some positive strategic insights, the challenges faced balance out the highlights, resulting in a moderate score.

Positive Factors

Telehealth Revenue Growth

The significant growth in telehealth revenue and EBITDA indicates strong demand and operational efficiency, supporting long-term business expansion.

AI Integration

AI integration enhances operational efficiency and patient care, positioning LifeMD for sustainable growth in the evolving telehealth market.

Debt-Free Status

Being debt-free improves financial stability and flexibility, allowing LifeMD to reinvest in growth opportunities without the burden of interest expenses.

Negative Factors

Declining Revenue Growth

The sharp decline in revenue growth poses a risk to LifeMD's market position and ability to sustain long-term operations without strategic adjustments.

High Leverage

High leverage limits financial flexibility and increases risk, potentially impacting LifeMD's ability to invest in growth and weather economic downturns.

Revised Financial Guidance

The downward revision in financial guidance reflects operational challenges and market uncertainties, impacting investor confidence and future growth prospects.

LifeMD Business Overview & Revenue Model

Company Description

LifeMD (LFMD) is a telehealth company that specializes in providing a range of virtual healthcare services, primarily focusing on chronic disease management, sexual health, and weight loss. The company leverages advanced technology to connect patients with licensed healthcare providers, offering personalized treatment plans and medications that are delivered directly to patients' homes. LifeMD's core products include telehealth consultations, prescription medications, and subscription-based health programs, catering to the growing demand for convenient and accessible healthcare solutions.

How the Company Makes Money

LifeMD generates revenue through multiple streams, primarily by charging patients for telehealth consultations and the sale of prescription medications. The company operates on a direct-to-consumer model, allowing it to reach a broad audience seeking convenient healthcare services. Significant revenue comes from subscription programs where patients pay for ongoing access to healthcare services and personalized treatment plans. Additionally, LifeMD may benefit from strategic partnerships with pharmacies and healthcare providers, which can enhance its service offerings and expand its customer base, further contributing to its earnings.

LifeMD Financial Statement Overview

Summary

LifeMD faces significant challenges with declining revenue growth and negative profitability margins. The balance sheet is heavily leveraged, posing financial risks. However, the company has shown strong free cash flow growth, which is a positive indicator of cash generation capability. Overall, while there are strengths in cash flow, the financial health of the company is concerning due to high leverage and negative profitability.

Income Statement

LifeMD has shown a significant decline in revenue growth with a TTM (Trailing-Twelve-Months) revenue growth rate of -95%. The gross profit margin remains strong at 91.97%, indicating efficient cost management. However, the net profit margin is negative at -5.21%, reflecting ongoing profitability challenges. EBIT and EBITDA margins are also weak, suggesting operational inefficiencies.

Balance Sheet

The company's balance sheet reveals a high debt-to-equity ratio of -10.78, indicating significant leverage and potential financial risk. Return on equity is positive at 2.33%, but this is due to negative equity, which is a concerning sign. The equity ratio is not favorable, suggesting a reliance on debt financing.

Cash Flow

LifeMD's cash flow statement shows a remarkable free cash flow growth of 318.98% in the TTM period, indicating improved cash generation. The operating cash flow to net income ratio is 0.25, and the free cash flow to net income ratio is 0.21, reflecting moderate cash flow efficiency despite negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	232.45M	212.45M	152.55M	119.03M	92.88M	37.29M
Gross Profit	215.05M	242.40M	133.65M	100.37M	74.88M	28.39M
EBITDA	8.55M	-6.65M	-7.89M	-35.92M	-53.43M	-57.48M
Net Income	-6.70M	-18.88M	-20.60M	-45.02M	-61.32M	-60.52M
Balance Sheet
Total Assets	73.56M	72.46M	58.48M	25.67M	49.92M	13.05M
Cash, Cash Equivalents and Short-Term Investments	36.23M	35.00M	33.15M	3.96M	41.33M	9.18M
Total Debt	22.05M	25.10M	18.93M	4.13M	1.85M	1.06M
Total Liabilities	73.18M	76.51M	52.91M	32.97M	24.10M	13.88M
Stockholders Equity	-1.78M	-5.49M	3.51M	-6.83M	26.85M	1.35M
Cash Flow
Free Cash Flow	13.27M	5.98M	86.95K	-35.83M	-36.49M	-12.53M
Operating Cash Flow	19.48M	17.51M	8.82M	-22.94M	-33.09M	-12.13M
Investing Cash Flow	-12.78M	-11.54M	-8.73M	-13.91M	-3.40M	-798.14K
Financing Cash Flow	-6.17M	-4.12M	29.10M	-528.20K	68.64M	21.00M

LifeMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Negative. The current price of 4.62 is below the 20-day moving average (MA) of 5.65, below the 50-day MA of 6.07, and below the 200-day MA of 7.77, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 23.13 is Positive, neither overbought nor oversold. The STOCH value of 8.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFMD.

LifeMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LFMD	44 Neutral	$240.41M	―	―	―	37.74%	69.79%
PETS	42 Neutral	$60.95M	―	―	―	-19.25%	14.47%
YI	38 Underperform	$38.38M	-3.73	―	―	-3.54%	77.98%

LifeMD Corporate Events

LifeMD Delays Quarterly Report Filing

LifeMD Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to the need for additional time to finalize adjustments correcting errors related to the over-recognition of revenue, amounting to approximately $4.6 million. These adjustments will not affect the company’s cash flow or cash position. The company expects to file the report within five calendar days following the original due date. While no significant changes in financial results are anticipated, LifeMD is evaluating the potential impact on its internal control over financial reporting. The notification was signed by Marc Benathen, the Chief Financial Officer, as the company continues its compliance efforts.

The most recent analyst rating on (LFMD) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Reschedules Q3 Earnings Call Amid Revenue Adjustments

On November 5, 2025, LifeMD announced the rescheduling of its third quarter 2025 earnings release and conference call to November 17, 2025, due to corrections identified in revenue recognition related to past data system migrations. The adjustments, impacting approximately $4.6 million or 1.4% of cumulative revenue, will not materially affect reported revenue results or the company’s cash flow and position. This decision reflects LifeMD’s commitment to accurate financial reporting and transparency, ensuring stakeholders are informed of the necessary adjustments without significant operational impact.

The most recent analyst rating on (LFMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Divests WorkSimpli Stake to Focus on Healthcare

On November 4, 2025, LifeMD, Inc. completed the sale of its majority interest in WorkSimpli Software LLC, valuing the company at approximately $65 million. This strategic divestiture allows LifeMD to focus on expanding its virtual care and pharmacy services, reinforcing its position as a pure-play healthcare company. The transaction, which involved a cash payment of $22 million at closing and potential additional earnings based on performance targets, is expected to strengthen LifeMD’s balance sheet and accelerate growth in its core business areas. The move is seen as a pivotal step in LifeMD’s transformation, enabling the company to concentrate on its primary healthcare offerings and expand into new clinical verticals.

The most recent analyst rating on (LFMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.